Weekly chemotherapy with cisplatin and paclitaxel in inoperable non-small cell lung cancer: an extended phase II study.
Weekly chemotherapy with cisplatin and paclitaxel in inoperable non-small cell lung cancer: an extended phase II study.
复制标题
每周用顺铂和紫杉醇化疗治疗不能手术的非小细胞肺癌：一项扩展的 II 期研究。
作者：
D. Ferrigno;G. Buccheri
背景
报道了一项顺铂/紫杉醇联合每周一次一线治疗非小细胞肺癌（NSCLC）的II期研究。
患者和方法
治疗包括每周静脉输注顺铂25 mg/m2和紫杉醇80 mg/m2。化疗持续至完成22周治疗计划、疾病进展、持续毒性或患者拒绝。
结果
79例患者入组研究。每例患者的中位输注次数为14次（范围0-22）。中位剂量强度为预计剂量的75%。毒性通常是可以接受的，从未危及生命。观察到7例完全缓解（4例病理证实）和27例部分缓解，总缓解率为43%。估计的中位生存期和中位进展时间分别为55周（95% CI：38-71）和37周（95% CI：31-44）。
结论
根据我们的经验，顺铂和紫杉醇每周联合用药耐受性好，活性高，生存期长。
BACKGROUND
A phase II study of a cisplatin/paclitaxel combination given on a weekly schedule in the front-line treatment of non-small cell lung cancer (NSCLC) is reported.
PATIENTS AND METHODS
Treatment consisted of an intravenous infusion of cisplatin, 25 mg/m2, and paclitaxel, 80 mg/m2, every week. Chemotherapy was continued until completion of a 22-week treatment plan, disease progression, persistent toxicity, or patient refusal.
RESULTS
Seventy-nine patients entered the study. The median number of infusions per patient was 14 (range 0-22). The median dose-intensity was 75% of that projected. Toxicity was generally acceptable, and never life-threatening. Seven complete responses (pathologically documented in 4 patients) and 27partial responses were observed for an overall response rate of 43%. The estimated median survival and median time to progression was 55 (95% CI: 38-71) and 37 weeks (95% CI: 31-44), respectively.
CONCLUSION
In our experience, the weekly combination of cisplatin and paclitaxel is well tolerated, active and associated with remarkably long survivals.
影响因子：
45.3
作者：
Bunn, PA
通讯作者：
Bunn, PA
影响因子：
45.3
作者：
Kelly, K;Crowley, J;Gandara, DR
通讯作者：
Gandara, DR
影响因子：
158.5
作者：
Schiller, JH;Harrington, D;Johnson, DH
通讯作者：
Johnson, DH